CSIMarket
 


Logicbio Therapeutics Inc   (LOGC)
Other Ticker:  
 

Cumulative Logicbio Therapeutics Inc 's Leverage Ratio for Trailing Twelve Months Period

LOGC's Leverage Ratio for Trailing Twelve Months Period and Total Liabilities, Equity growth


Select the Comparisons : Select the Ratio:

LOGC Leverage Ratio for Trailing Twelve Months Period

(Sep 30 2022)
III. Quarter
(Jun 30 2022)
II. Quarter
(Mar 31 2022)
I. Quarter
(Dec 31 2021)
IV. Quarter
(Sep 30 2021)
III. Quarter
Y / Y Equity Growth -59.4 % -53.78 % -54.06 % -49.98 % 73.9 %
Y / Y Total Liabilities Growth -22.19 % -20.32 % 20.22 % 49.52 % 31.26 %
Leverage Ratio for Trailing Twelve Months Period 0.98 0.83 0.73 0.58 0.44
Total Ranking # 2357 # 2151 # 2097 # 1712 # 1113
Seq. Equity Growth -24.02 % -16.84 % -18.93 % -20.73 % -13.51 %
Seq. Total Liabilities Growth -14.24 % -1.74 % -17.58 % 12.02 % -12.17 %


Leverage Ratio for Trailing Twelve Months Period Comment for 12 Months ending at Sep 30 2022
On the trailing twelve months basis Despite debt repayement of -14.24% in III. Quarter, Leverage Ratio for Trailing Twelve Months Period improved to 0.98, above Logicbio Therapeutics Inc 's average Leverage Ratio for Trailing Twelve Months Period.
Leverage Ratio for Trailing Twelve Months Period is the average cumulative value over the last four quarters.

Among companies in Biotechnology & Pharmaceuticals industry 137 other companies have achieved lower Leverage Ratio for Trailing Twelve Months Period than Logicbio Therapeutics Inc . While total ranking remained unchanged compare to previous quarter at no. .

What is Leverage Ratio?
Who are LOGC's Customers?
Leverage Ratio for Trailing Twelve Months Period Company Ranking
Within: No.
Industry # 138
Sector # 805
S&P 500 # 2347


Leverage Ratio for Trailing Twelve Months Period Statistics
High Average Low
1.17 0.52 0.09
(Sep 30 2022)   (Sep 30 2019)




Companies with similar average Leverage Ratio for Trailing Twelve Months Period for 12 months ending Sep 30 2022, within Biotechnology & Pharmaceuticals Industry Leverage Ratio for Trailing Twelve Months Period
Valneva Se  2.69 
Axcella Health Inc   2.43 
Acorda Therapeutics Inc   2.41 
Sab Biotherapeutics Inc   2.19 
Ladrx Corporation  2.13 
Nanostring Technologies Inc   2.10 
Eloxx Pharmaceuticals Inc   2.07 
Senti Biosciences Inc   2.06 
Oyster Point Pharma Inc   1.97 
Alector Inc   1.88 
Gilead Sciences Inc   1.78 
Precision Biosciences Inc  1.65 
Codiak Biosciences Inc   1.64 
Adaptimmune Therapeutics Plc  1.58 
Taysha Gene Therapies Inc   1.53 
Tracon Pharmaceuticals Inc   1.43 
Adma Biologics Inc   1.33 
Humacyte Inc   1.31 
Innate Pharma Sa  1.30 
Erytech Pharma S a   1.21 
Biogen Inc   1.11 
Outlook Therapeutics Inc   1.05 
Fennec Pharmaceuticals Inc   1.05 
Armata Pharmaceuticals Inc   1.02 
Windtree Therapeutics Inc  1.00 
Aceragen Inc   0.96 
Allena Pharmaceuticals Inc.  0.95 
Genfit S a   0.95 
Applied Genetic Technologies Corporation  0.94 
Meiragtx Holdings Plc  0.94 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com